Login / Signup

Ligelizumab for Chronic Spontaneous Urticaria.

Marcus MaurerAna M Giménez-ArnauGordon SussmanMartin MetzDiane R BakerAndrea BauerJonathan A BernsteinRandolf BrehlerChia-Yu ChuWen-Hung ChungInna DanilychevaClive GrattanJacques HébertConstance KatelarisMichael MakrisRaisa MeshkovaSinisa SavicRodney SinclairKarl SitzPetra StaubachBettina WediJürgen LöfflerAvantika BarveKenneth KobayashiEva HuaThomas SeverinReinhold Janocha
Published in: The New England journal of medicine (2019)
A higher percentage of patients had complete control of symptoms of chronic spontaneous urticaria with ligelizumab therapy of 72 mg or 240 mg than with omalizumab or placebo. (Funded by Novartis Pharma; ClinicalTrials.gov number, NCT02477332.).
Keyphrases
  • end stage renal disease
  • ejection fraction
  • chronic kidney disease
  • newly diagnosed
  • peritoneal dialysis
  • prognostic factors
  • clinical trial
  • physical activity
  • sleep quality
  • chemotherapy induced